Global Diagnostic Antibodies Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Diagnostic Antibodies Market Insights, Forecast to 2034
Diagnostic Antibody detection is still the primary approach for confirmation of Lyme borreliosis. Quantitative EIAs (enzyme immune assays) are used as a first-line test with the possibility of supplementary western blotting (WB). Specific antibodies are detectable in serum and in CSF.
Market Analysis and InsightsGlobal Diagnostic Antibodies Market
Global Diagnostic Antibodies market is expected to reach to US$ 27110 million in 2024, with a positive growth of %, compared with US$ 25970 million in 2022. Backed with the increasing demand from downstream industries, Diagnostic Antibodies industry is evaluated to reach US$ 38350 million in 2029. The CAGR will be 6.0% during 2024 to 2029.
The global diagnostic antibodies market refers to the market for antibodies used in diagnostic tests and assays for various diseases and conditions. Diagnostic antibodies play a crucial role in detecting and identifying specific biomarkers or targets in patient samples, aiding in the accurate diagnosis and monitoring of various diseases.
Key factors driving the growth of the global diagnostic antibodies market include
Increasing prevalence of chronic and infectious diseasesThe growing burden of chronic diseases, such as cancer, cardiovascular diseases, and autoimmune disorders, has created a demand for accurate diagnostic tools. Diagnostic antibodies, with their high specificity and sensitivity, enable the detection of disease markers and facilitate early diagnosis and treatment.
Advancements in personalized medicineThe shift towards personalized medicine, where treatments are tailored to an individual’s specific characteristics and needs, has increased the demand for precise diagnostic tools. Diagnostic antibodies offer the ability to identify specific biomarkers associated with diseases, enabling personalized treatment strategies.
Technological advancements in antibody productionThe development of advanced techniques for antibody production, such as recombinant DNA technology and phage display technology, has revolutionized the diagnostic antibodies market. These technologies allow for the production of highly specific and reproducible antibodies, enhancing the accuracy of diagnostic tests.
Growing demand for point-of-care testingPoint-of-care testing (POCT) has gained significant popularity due to its convenience and rapid results. Diagnostic antibodies are essential components of many POCT devices, enabling on-site diagnosis and immediate treatment decisions.
Increasing healthcare expenditure and focus on early diagnosisWith rising healthcare expenditures and a growing emphasis on preventive healthcare, there is a greater focus on early disease detection. Diagnostic antibodies aid in the early diagnosis of diseases, enabling timely intervention and improved patient outcomes.
The global diagnostic antibodies market is highly competitive, with several key players dominating the market. These include Thermo Fisher Scientific, Abcam plc, Bio-Rad Laboratories, Inc., Merck KGaA, and Beckman Coulter, among others. These companies are actively engaged in research and development activities to develop innovative diagnostic antibodies and expand their product portfolios.
In summary, the global diagnostic antibodies market is driven by the increasing prevalence of chronic and infectious diseases, advancements in personalized medicine, technological advancements in antibody production, growing demand for point-of-care testing, and the focus on early diagnosis. The market is expected to witness further growth as the demand for accurate and reliable diagnostic tools continues to rise.
Report Covers
This report presents an overview of global Diagnostic Antibodies market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Diagnostic Antibodies market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Aytu BioScience, Inc.
Agilent Technologies, Inc.
Abbott
Abcam plc.
Boehringer Ingelheim International GmbH
Bio-Rad Laboratories, Inc.
Roche Holding AG
Thermo Fisher Scientific
Merck KGaA
Beckman Coulter
Novus Biologicals
Cell Signaling Technology
Segment by Type
Monoclonal Antibodies
polyclonal Antibodies
Recombinant Polyclonal Antibodies
Others
Hospitals
Diagnostic Centre
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Diagnostic Antibodies introduction, etc. Diagnostic Antibodies Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Diagnostic Antibodies
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Diagnostic Antibodies Market
Global Diagnostic Antibodies market is expected to reach to US$ 27110 million in 2024, with a positive growth of %, compared with US$ 25970 million in 2022. Backed with the increasing demand from downstream industries, Diagnostic Antibodies industry is evaluated to reach US$ 38350 million in 2029. The CAGR will be 6.0% during 2024 to 2029.
The global diagnostic antibodies market refers to the market for antibodies used in diagnostic tests and assays for various diseases and conditions. Diagnostic antibodies play a crucial role in detecting and identifying specific biomarkers or targets in patient samples, aiding in the accurate diagnosis and monitoring of various diseases.
Key factors driving the growth of the global diagnostic antibodies market include
Increasing prevalence of chronic and infectious diseasesThe growing burden of chronic diseases, such as cancer, cardiovascular diseases, and autoimmune disorders, has created a demand for accurate diagnostic tools. Diagnostic antibodies, with their high specificity and sensitivity, enable the detection of disease markers and facilitate early diagnosis and treatment.
Advancements in personalized medicineThe shift towards personalized medicine, where treatments are tailored to an individual’s specific characteristics and needs, has increased the demand for precise diagnostic tools. Diagnostic antibodies offer the ability to identify specific biomarkers associated with diseases, enabling personalized treatment strategies.
Technological advancements in antibody productionThe development of advanced techniques for antibody production, such as recombinant DNA technology and phage display technology, has revolutionized the diagnostic antibodies market. These technologies allow for the production of highly specific and reproducible antibodies, enhancing the accuracy of diagnostic tests.
Growing demand for point-of-care testingPoint-of-care testing (POCT) has gained significant popularity due to its convenience and rapid results. Diagnostic antibodies are essential components of many POCT devices, enabling on-site diagnosis and immediate treatment decisions.
Increasing healthcare expenditure and focus on early diagnosisWith rising healthcare expenditures and a growing emphasis on preventive healthcare, there is a greater focus on early disease detection. Diagnostic antibodies aid in the early diagnosis of diseases, enabling timely intervention and improved patient outcomes.
The global diagnostic antibodies market is highly competitive, with several key players dominating the market. These include Thermo Fisher Scientific, Abcam plc, Bio-Rad Laboratories, Inc., Merck KGaA, and Beckman Coulter, among others. These companies are actively engaged in research and development activities to develop innovative diagnostic antibodies and expand their product portfolios.
In summary, the global diagnostic antibodies market is driven by the increasing prevalence of chronic and infectious diseases, advancements in personalized medicine, technological advancements in antibody production, growing demand for point-of-care testing, and the focus on early diagnosis. The market is expected to witness further growth as the demand for accurate and reliable diagnostic tools continues to rise.
Report Covers
This report presents an overview of global Diagnostic Antibodies market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Diagnostic Antibodies market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Aytu BioScience, Inc.
Agilent Technologies, Inc.
Abbott
Abcam plc.
Boehringer Ingelheim International GmbH
Bio-Rad Laboratories, Inc.
Roche Holding AG
Thermo Fisher Scientific
Merck KGaA
Beckman Coulter
Novus Biologicals
Cell Signaling Technology
Segment by Type
Monoclonal Antibodies
polyclonal Antibodies
Recombinant Polyclonal Antibodies
Others
Segment by Application
Hospitals
Diagnostic Centre
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Diagnostic Antibodies introduction, etc. Diagnostic Antibodies Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Diagnostic Antibodies
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices